Abstract

Objective To investigate the effect of antiviral therapy on the prevention and prognosis of hepatitis B virus (HBV) reactivation after HBV DNA negative HBV related hepatocellular carcinoma (HBVR-HCC) transarterial chemoembolization (TACE). Methods 62 patients with HBVR-HCC were selected in our hospital from January 2013 to June 2014 in accordance with selection criteria. According to different treatment options, they were divided into control group (n=31) and study group (n=31). The control group was only treated with TACE, while the study group was treated with TACE and entecavir. At 6th, 12th, and 18th month after operation, two groups of patients were followed up. The clinical effect of the two groups, the reactivation of HBV, and the long-term survival rate were analyzed. The changes of liver function, blood coagulation function, alpha fetal protein, and Child-Pugh score were compared between the two groups before and after treatment. Results There were no statistically significant differences in the objective remission rate and disease control rate between the study group and the control group (51.61% vs.45.16%, 87.10% vs.83.87%; P>0.05). There was statistically significant difference in the positive rate of HBV DNA between the study group and the control group (3.22% vs.25.81%, P 0.05); the level of PT at 6th month after operation, the level of AFP at 12th month after operation, the levels of PT and AFP at 18th month after operation in the study group were significantly better than those in the control group, with statistically significant differences (P 0.05); the survival rate in the study group at 18th month after operation was significantly higher than that in the control group (64.52% vs.35.48%), with statistically significant difference (P<0.05). Conclusion The combination of antiviral therapy in the treatment of hepatitis B virus DNA negative HBVR-HCC patients during the period of TACE can effectively inhibit the reactivation of HBV, improve the clinical efficacy and the long-term prognosis, and prolong the survival time. Key words: Antiviral therapy; Hepatitis B virus DNA negative; HBV related hepatocellular carcinoma; Transarterial chemoembolization

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.